Rocket Doctor AI Announces Strong Q3 Momentum Driven by U.S. Expansion, New Payer Contracts and Platform Growth

Executive Summary

• Rocket Doctor AI Inc. reported Q3 2025 results, showing revenue of C$529,123 (up from Q2) but a net loss of C$3.5 M ($0.05 per share).
• Completed an oversubscribed non‑brokered private placement and special warrant financing, raising gross proceeds of C$4.23 million, improving cash to C$1.89 M.
• Announced new in‑network contracts with major U.S. insurers covering >13 million members, expanding the company’s U.S. addressable market (now ~5% of revenue).

Key Details

• Financial Highlights
• Revenue Q3 2025: C$529,123 vs. C$512,756 in Q2 2025 and C$10,990 in Q3 2024.
• Gross margin Q3 2025: 88% (down from 89% in Q2).
• Net comprehensive loss: C$3.5 M ($0.05 per share) vs. C$2.7 M in Q2.

• Adjusted EBITDA loss: C$1.8 M (vs. C$1.7 M in Q2).

• Financing

• Private placement & special warrant financing closed on Aug 21, 2025.
• Gross proceeds: C$4.23 million (oversubscribed).

• Resulting cash balance as of Sep 30, 2025: C$1.89 M (up from C$0.12 M at June‑30).

• U.S. In‑Network Expansion

• New payer agreements in California, New York, and Maryland (Medicaid & Medicare).

• Coverage now extends to >13 million insured members across the U.S.

• Operational Updates

• Post‑acquisition revenue growth driven by Rocket Doctor Inc. acquisition completed Q2 2025.

• Partnerships:

  • July 10: Healthy Aging Program pilot with EngageWell IPA, funded $1 M by CVS Health Foundation.
  • July 16: Emergency department diversion program for Canada’s ED crisis.
  • Sep 9: Expansion to 50 independent pharmacies (16,500+ appointments).
  • Sep 15: First municipal partnership with Town of Bruderheim, Alberta (Alberta Health coverage).

• Product & Technology Progress

• Core platform re‑architecture completed; API layer enhanced for scalability.
• Knowledge‑Based Editor and GLM enhancements; $180 k invested H1 2025, annualized maintenance ~$250 k.
• AI Pharmacy Assistant integration with >50 pharmacies underway.

• RD Connect triage pilot in a Canadian provincial network; broader rollout planned late 2025/early 2026.

• Future Outlook

• Anticipates initial revenue from U.S. payer contracts to begin Q1 2026, contributing incremental growth in Q4 2025 and 2026.
• NIH SBIR grant awarded to Treatment USA (potential >US$500 k) for medical history data integration.

Notable Quotes

• Dr. Essam Hamza, CEO: “Despite expected summer seasonality, we are pleased to report continued sequential organic revenue growth… The new in‑network agreements expand our ability to deliver care to more than 13 million insured members… positioning us for accelerated growth in the U.S. market throughout 2026.”